As of September 30, the company had cash and cash equivalents of approximately $27.7M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Inmune Bio to Host Q3 Results Conference Call
- INmune Bio CEO to Speak at Maxim Growth Summit
- Inmune Bio’s Promising Pipeline and Strategic Positioning Support Buy Rating Despite Recent Challenges
- Inmune Bio Submits Manuscript on Alzheimer’s Trial
- INmune Bio submits Phase 2 MINDFuL trial results to npj Dementia